Abstract
SUMMARY: Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.
ABBREVIATIONS:
- IDH
- isocitrate dehydrogenase
- IDHmut
- IDH mutant
- IDHwt
- IDH wild-type
- WHO
- World Health Organization
- HG
- 2-hydroxyglutarate
- nCET
- non-contrast-enhancing tumor
- cIMPACT-NOW
- Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
Footnotes
Arian Lasocki was supported by a Peter MacCallum Cancer Foundation Discovery Partner Fellowship.
Disclosures: Arian Lasocki—RELATED: Grant: Peter MacCallum Cancer Foundation, Comments: Supported by a Peter MacCallum Cancer Foundation Discovery Partner Fellowship.* *Money paid to the institution.
- © 2020 by American Journal of Neuroradiology
Indicates open access to non-subscribers at www.ajnr.org